Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
gyrA parC double mutant response to norfloxacin treatment: time course (I)
PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet
Temperature upshift in E coli gyrBT strain, time series
PubMed Full text in PMC Similar studies Analyze with GEO2R
Stationary phase in LB, genomic DNA reference
Ecoli DH5alpha, pUC overexpression in LB + Amp vs no pUC
Novobiocin treatment in LB
Gamma treatment in Davis, timecourse
Anaerobic growth in M9 + glucose + fumarate
Anaerobic growth in M9 + glucose
Anaerobic growth in M9 + glucose + fumarate,genomic DNA reference
Anaerobic growth in M9 + glucose, genomic DNA reference
Ecoli W3110_0.01 M sodium azide treatment vs untreated, timecourse
Recovery from stationary phase in 10 mM Na-P (pH 7.5) + 0.2 % glucose
Recovery from stationary phase in 10 mM Na-P (pH 7.5)
Ecoli C600 (gyrArparCr) Norfloxacin treatment (50 ug/ml) in LB, timecourse
Ecoli C600 (gyrArparCr) Norfloxacin treatment (15 ug/ml) in LB, timecourse
Ecoli C600 Norfloxacin treatment (50 ug/ml) in LB, timecourse
Balanced growth of Ecoli MG1655/pTrc99a(NOX-) at different growth rates
Balanced growth of Ecoli MG1655/pTrc99a(NOX+) at different growth rates
Recovery from stationary phase in LB + glucose at OD 1.0
Recovery from stationary phase in LB + 0.2 % glucose
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on